Voyager Therapeutics Aligns With CHDI Foundation TO Develop Novel Gene Therapy For Huntington's Disease

Voyager Therapeutics, Inc. VYGR revealed that it aligned with CHDI Foundation, Inc. (CHDI) to advance its VY-HTT01 program, which is an adeno-associated virus (AAV)-mediated gene-silencing therapy for Huntington's disease.

The company disclosed that its alliance would establish upon a previous collaboration between CHDI and Sanofi Genzyme. This included funding from CHDI to support its readiness for and filing of an investigational NDA and the completion of a Phase 1 clinical trial. The company indicated that it would reimburse CHDI of its program upon VY-HTT01 on achieving some commercial milestones.

Voyager Therapeutics' president and CEO, Steven Paul, commented, "The effort and expertise that Voyager and Sanofi Genzyme continue to commit to the VY-HTT01 program, now further strengthened with CHDI's extensive experience in Huntington's disease research, puts us in a strong position to advance the clinical development of a potential disease-modifying medicine for patients suffering from Huntington's disease."

Voyager Therapeutics closed Friday's session at $12.68, losing $0.18, or 1.40 percent.